We compared the efficacy of 2 to bortezomib, a proteasome inhibitor and standard treatment for multiple myeloma and lymphomas, and also explored the possibility of synergistic proteasomal and HPSE inhibitor treatment. The gene discussed is HPSE; the disease is lymphoma.